PDE 2015: cAMP Signaling, Protein Kinase A (PKA) and Phosphodiesterases (PDEs): How Genetics Changed the Way We Look at One of the Most Studied Signaling Pathways

Constantine A. Stratakis; Fahrettin Kelestimur; Jérôme Bertherat

doi:10.1055/s-0043-106858

Hormone and Metabolic Research, Table of Contents

Horm Metab Res 2017; 49(04): 237-239
DOI: 10.1055/s-0043-106858

Editorial

PDE 2015: cAMP Signaling, Protein Kinase A (PKA) and Phosphodiesterases (PDEs): How Genetics Changed the Way We Look at One of the Most Studied Signaling Pathways

Constantine A. Stratakis

¹Section on Endocrinology & Genetics, Program on Developmental Endocrinology & Genetics, Eunice Kennedy Shriver National Institute of Child Health & Human Development, National Institutes of Health, Bethesda, USA

,

Fahrettin Kelestimur

²Department of Endocrinology, Erciyes University Medical School, Kayseri, Turkey

,

Jérôme Bertherat

³Endocrinology Department, Hôpital Cochin, AP-HP, & Institut Cochin, INSERM U1016, Université Paris Descartes, Paris, France

› Author Affiliations

Abstract

This special issue of Hormone and Metabolic Research presents the proceedings of the 4th international workshop (PDE 2015) on cyclic AMP (cAMP)/protein kinase A (PKA) signaling and phosphodiesterases (PDEs). The meeting took place at Erciyes University, in Kayseri, Turkey, ([Fig. 1]) and followed the previous workshops that were held in Paris, France, and in Bethesda, MD [1] [2]. We are indebted to the host, one of the newest and most advanced universities in Turkey, an example of how science can be inclusive and bridge not only disciplines, but also cultures. We visited the historic Cappadocia region with its rich Greek heritage, and enjoyed the local food and traditions, as well as the beautiful Ottoman architecture of Kayseri and its surroundings.

Full Text

References

References
1 Stratakis CA. Cyclic AMP, protein kinase A, and phosphodiesterases: Proceedings of an international workshop. Horm Metab Res 2012; 44: 713-715
2 Stratakis CA, Bertherat J. PDE 2013, Paris, France: Another exciting workshop for cyclic AMP, protein kinase A, and phosphodiesterases. Horm Metab Res 2014; 46: 825-826
3 Mantovani G, Elli FM, Spada A. GNAS epigenetic defects and pseudohypoparathyroidism: Time for a new classification?. Horm Metab Res 2012; 44: 716-723
4 Zhang S, Kaplan FS, Shore EM. Different roles of GNAS and cAMP signaling during early and late stages of osteogenic differentiation. Horm Metab Res 2012; 44: 724-731
5 Bastepe M. Relative functions of Gαs and its extra-large variant XLαs in the endocrine system. Horm Metab Res 2012; 44: 732-740
6 Yu B, Ragazzon B, Rizk-Rabin M, Bertherat J. Protein kinase A alterations in endocrine tumors. Horm Metab Res 2012; 44: 741-748
7 Silve C, Clauser E, Linglart A. Acrodysostosis. Horm Metab Res 2012; 44: 749-758
8 Hussain MA, Stratakis CA, Kirschner L. Prkar1a in the regulation of insulin secretion. Horm Metab Res 2012; 44: 759-765
9 Knight WE, Yan C. Cardiac cyclic nucleotide phosphodiesterase: Function, regulation, and therapeutic prospects. Horm Metab Res 2012; 44: 766-775
10 Ahmad F, Degerman E, Manganiello VC. Cyclic nucleotide phosphodiesterase 3 signaling complexes. Horm Metab Res 2012; 44: 776-785
11 Vincent P, Castro LR, Gervasi N, Guiot E, Brito M, Paupardin-Tritsch D. PDE4 control on cAMP/PKA compartmentation revealed by biosensor imaging in neurons. Horm Metab Res 2012; 44: 786-789
12 Tsai LC, Beavo JA. Regulation of adrenal steroidogenesis by the highaffinity phosphodiesterase 8 family. Horm Metab Res 2012; 44: 790-794
13 Stratakis CA, Kirschner LS. Clinical and genetic analysis of primary bilateral adrenal diseases (micro- and macronodular disease) leading to Cushing syndrome. Horm Metab Res 1998; 30: 456-463
14 Stratakis CA, Marx SJ. Multiple endocrine neoplasias in the era of translational medicine. Horm Metab Res 2005; 37: 343-346
15 Stratakis CA. Adrenocortical tumors, primary pigmented adrenocortical disease (PPNAD)/Carney complex, and other bilateral hyperplasias: the NIH studies. Horm Metab Res 2007; 39: 467-473
16 Boikos SA, Horvath A, Heyerdahl S, Stein E, Robinson-White A, Bossis I, Bertherat J, Carney JA, Stratakis CA. Phosphodiesterase 11A expression in the adrenal cortex, primary pigmented nodular adrenocortical disease, and other corticotropin-independent lesions. Horm Metab Res 2008; 40: 347-353
17 Calebiro D, Sungkaworn T, Maiellaro I. Real-time monitoring of GPCR/cAMP signalling by FRET and single-molecule microscopy. Horm Metab Res 2014; 46: 827-832
18 Rogne M, Taskén K. Compartmentalization of cAMP signaling in adipogenesis, lipogenesis, and lipolysis. Horm Metab Res 2014; 46: 833-840
19 Weinstein LS. Role of Gsα in central regulation of energy and glucose metabolism. Horm Metab Res 2014; 46: 841-844
20 Insel PA, Wilderman A, Zhang L, Keshwani MM, Zambon AC. Cyclic AMP/ PKA-promoted apoptosis: Insights from studies of S49 lymphoma cells. Horm Metab Res 2014; 46: 854-862
21 Peverelli E, Giardino E, Vitali E, Treppiedi D, Lania AG, Mantovani G. Filamin A in somatostatin and dopamine receptor regulation in pituitary and the role of cAMP/PKA dependent phosphorylation. Horm Metab Res 2014; 46: 845-853
22 Szarek E, Stratakis CA. Phosphodiesterases and adrenal cushing in mice and humans. Horm Metab Res 2014; 46: 863-868
23 Espiard S, Ragazzon B, Bertherat J. Protein kinase A alterations in adrenocortical tumors. Horm Metab Res 2014; 46: 869-875
24 Louiset E, Duparc C, Groussin L, Gobet F, Desailloud R, Barrande G, Reznik Y, Bertherat J, Prévost G, Lefebvre H. Abnormal sensitivity to glucagon and related peptides in primary adrenal Cushing’s syndrome. Horm Metab Res 2014; 46: 876-882
25 Basso F, Rocchetti F, Rodriguez S, Nesterova M, Cormier F, Stratakis CA, Ragazzon B, Bertherat J, Rizk-Rabin M. Comparison of the effects of PRKAR1A and PRKAR2B depletion on signaling pathways, cell growth, and cell cycle control of adrenocortical cells. Horm Metab Res 2014; 46: 883-888
26 Berthon A, Stratakis CA. From β-catenin to ARM-repeat proteins in adrenocortical disorders. Horm Metab Res 2014; 46: 889-896
27 London E, Lodish M, Keil M, Lyssikatos C, de la Luz Sierra M, Nesterova M, Stratakis CA. Not all glucocorticoid-induced obesity is the same: Differences in adiposity among various diagnostic groups of Cushing syndrome. Horm Metab Res 2014; 46: 897-903
28 Liu S, Shapiro JM, Saloustros E, Stratakis CA. Bone abnormalities in mice with protein kinase A (PKA) defects reveal a role of cyclic AMP signaling in bone stromal cell-dependent tumor development. Horm Metab Res 2016; 48: 714-725
29 Broecker-Preuss M, Baten J, Sheu-Grabellus SY, Görges R, Bockisch A, Schmid KW, Führer D, Mann K. Expression of the cAMP binding protein EPAC1 in thyroid tumors and growth regulation of thyroid cells and thyroid carcinoma cells by EPAC proteins. Horm Metab Res 2015; 47: 200-208
30 Collins MT, Stratakis CA. Bone formation, growth, and repair. Horm Metab Res 2016; 48: 687-688
31 Hsiao EC, Millard SM, Nissenson RA. Gs/Gi regulation of bone cell differentiation: Review and insights from engineered receptors. Horm Metab Res 2016; 48: 689-699
32 Chrysostomou PP, Lodish MB, Turkbey EB, Papadakis GZ, Stratakis CA. Use of 3-dimensional volumetric modeling of adrenal gland size in patients with primary pigmented nodular adrenocortical disease. Horm Metab Res 2016; 48: 242-246
33 Azevedo MF, Faucz FR, Bimpaki E, Horvath A, Levy I, de Alexandre RB, Ahmad F, Manganiello V, Stratakis CA. Clinical and molecular genetics of the phosphodiesterases (PDEs). Endocr Rev 2014; 35: 195-233
34 Torres-Quesada O, Röck R, Stefan E. Systematic quantification of GPCR/cAMP-controlled protein kinase A interactions. Horm Metab Res 2017; 49: 240-249
35 Elli FM, Boldrin V, Pirelli A, Spada A, Mantovani G. The complex GNAS imprinted locus and mesenchymal stem cells differentiation. Horm Metab Res 2017; 49: 250-258
36 Treppiedi D, Peverelli E, Giardino E, Ferrante E, Calebiro D, Spada A, Mantovani G. Somatostatin receptor type 2 (SSTR2) internalization and intracellular trafficking in pituitary GH-secreting adenomas: Role of scaffold proteins and implications for pharmacological resistance. Horm Metab Res 2017; 49: 259-268
37 Duparc C, André C, Ménard JF, Godouet-Getti B, Wils J, Cailleux AF, Moreau-Grangé L, Louiset E, Lefebvre H. L-lysine acts as a serotonin type 4 receptor antagonist to counteract in vitro and in vivo the stimulatory effect of serotonergic agents on aldosterone secretion in man. Horm Metab Res 2017; 49: 269-275
38 Chu DT, Tao Y, Taskén K. OPA1 in lipid metabolism: Function of OPA1 in lipolysis and thermogenesis of adipocytes. Horm Metab Res 2017; 49: 276-285
39 Hernández-Ramírez LC, Trivellin G, Stratakis CA. Role of phosphodiesterases on the function of aryl hydrocarbon receptor-interacting protein (AIP) in the pituitary gland and on the evaluation of AIP gene variants. Horm Metab Res 2017; 49: 286-295
40 Haidar M, Ramdani G, Kennedy EJ, Langsley G. PKA and apicomplexan parasite diseases. Horm Metab Res 2017; 49: 296-300
41 Di Dalmazi G, Beuschlein F. PRKACA mutations in adrenal adenomas: genotype/phenotype correlations. Horm Metab Res 2017; 49: 301-306
42 Calebiro D, Bathon K, Weigand I. Mechanisms of aberrant PKA activation by Cα subunit mutations. Horm Metab Res 2017; 49: 307-314
43 Stratakis CA. E pluribus unum? The main protein kinase A catalytic subunit (PRKACA), a likely oncogene, and cortisol-producing tumors. J Clin Endocrinol Metab 2014; 99: 3629-3633